Below are the most recent publications written about "Antibodies, Neutralizing" by people in Profiles.
-
Almeida GG, Pinto JA, Pinto PM, da Silva LB, Andrade LAF, Valiate BVS, Zini N, Bagno FF, Rivelli GG, Louren?o KL, Souza JPC, Gomes IP, de Castro NS, Maia ALC, de Carvalho AF, Alves JC, de Castro JT, Li G, da Rocha Fernandes G, Alves PA, Diniz RC, Daher AB, de Souza RP, Teixeira SMR, Fernandes APSM, Gazzinelli RT, da Costa Santiago H. Safety and immunogenicity of SpiN-Tec, a T-cell based RBD-Nucleocapsid chimeric vaccine for COVID-19. Vaccine. 2025 Oct 03; 64:127756.
-
Sullivan-B?lyai JZ, Allen LB, Cannon R, Cohane KP, Dunzo E, Goldwater R, StCyr K, Wang Y, Klempner MS. A Phase 1 Study in Healthy Subjects to Evaluate the Safety and Pharmacokinetics of a Human Monoclonal Antibody (S315) Against Diphtheria Toxin. J Infect Dis. 2025 Sep 15; 232(3):534-539.
-
Ardeshir A, O'Hagan D, Mehta I, Shandilya S, Hopkins LLJ, Adamson L, Kuroda MJ, Hahn PA, da Costa LAB, Fuchs SP, Martinez-Navio JM, Gardner MR, Van Rompay KKA, Magnani DM, Lifson JD, Gao G, Farzan M, Desrosiers RC, Das J, Martins MA. Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life. Nature. 2025 Sep; 645(8082):1020-1028.
-
Matsuda K, Harrison M, Wettstein E, Pederson J, Pullano AA, Bolkhovitinov L, Kim B, Steinberg I, Griesman T, Stuccio S, Rogan D, Patamawenu A, Shofner T, Wright NE, Webber JD, Van't Veer F, Roenicke R, Koory E, Roeder PM, Ober E, Leach B, Tsybovsky Y, Stephens T, Del Moral-Sanchez I, Bontjer I, McGinnes-Cullen LW, Chu E, Liang J, Torres JL, Lin RN, Tran AS, Dziubla G, Serebryannyy L, Narpala S, Lin B, Castro M, Ozorowski G, Ward AB, Sanders RW, Kwong PD, Guenaga J, Wyatt R, Morrison T, Connors M. Antigen persistence and TLR stimulation contribute to induction of a durable HIV-1-specific neutralizing antibody response. Nat Commun. 2025 Jun 03; 16(1):5162.
-
Youssef N, Gurev S, Ghantous F, Brock KP, Jaimes JA, Thadani NN, Dauphin A, Sherman AC, Yurkovetskiy L, Soto D, Estanboulieh R, Kotzen B, Notin P, Kollasch AW, Cohen AA, Dross SE, Erasmus J, Fuller DH, Bjorkman PJ, Lemieux JE, Luban J, Seaman MS, Marks DS. Computationally designed proteins mimic antibody immune evasion in viral evolution. Immunity. 2025 Jun 10; 58(6):1411-1421.e6.
-
Haidar G, Thomas S, Loubet P, Baker RI, Benfield T, Boonyaratanakornkit J, Kiertiburanakul S, Kim AHJ, Longbrake EE, Molina JM, Paredes R, Tucker D, Uriel A, Weinmann-Menke J, Aksyuk AA, Clegg LE, Currie A, Yang H, Flyrin K, Gibbs M, Shroff M, Perez JL, Chang LJ, Cohen TS. Efficacy and safety of sipavibart for prevention of COVID-19 in individuals who are immunocompromised (SUPERNOVA): a randomised, controlled, double-blind, phase 3 trial. Lancet Infect Dis. 2025 Jul; 25(7):813-826.
-
Dankwa S, Kosman C, Dennis M, Giorgi EE, Vuong K, Pahountis I, Garza A, Binuya C, McCarthy J, Mayer BT, Ngo JT, Enemuo CA, Carnathan DG, Stanfield-Oakley S, Berendam SJ, Weinbaum C, Engelman K, Magnani DM, Chan C, Ferrari G, Silvestri G, Amara RR, Chahroudi A, Permar SR, Fouda GG, Goswami R. A novel HIV triple broadly neutralizing antibody (bNAb) combination-based passive immunization of infant rhesus macaques achieves durable protective plasma neutralization levels and mediates anti-viral effector functions. PLoS One. 2024; 19(11):e0312411.
-
Hojo-Souza NS, de Castro JT, Rivelli GG, Azevedo PO, Oliveira ER, Faustino LP, Salazar N, Bagno FF, Carvalho AF, Rattis B, Louren?o KL, Gomes IP, Assis BRD, Piccin M, Fonseca FG, Durigon E, Silva JS, de Souza RP, Goulart GAC, Santiago H, Fernandes APS, Teixeira SR, Gazzinelli RT. SpiN-Tec: A T cell-based recombinant vaccine that is safe, immunogenic, and shows high efficacy in experimental models challenged with SARS-CoV-2 variants of concern. Vaccine. 2024 12 02; 42(26):126394.
-
Escalante GM, Reidel IG, Mutsvunguma LZ, Cua S, Tello BA, Rodriguez E, Farelo MA, Zimmerman C, Muniraju M, Li H, Govindan AN, Axthelm MK, Wong SW, Ogembo JG. Multivalent MVA-vectored vaccine elicits EBV neutralizing antibodies in rhesus macaques that reduce EBV infection in humanized mice. Front Immunol. 2024; 15:1445209.
-
Marchitto L, Richard J, Pr?vost J, Tauzin A, Yang D, Chiu T-J, Chen H-C, D?az-Salinas MA, Nayrac M, Benlarbi M, Beaudoin-Bussi?res G, Anand SP, Dionne K, B?langer ?, Chatterjee D, Medjahed H, Bourassa C, Tolbert WD, Hahn BH, Munro JB, Pazgier M, Smith AB, Finzi A. The combination of three CD4-induced antibodies targeting highly conserved Env regions with a small CD4-mimetic achieves potent ADCC activity. J Virol. 2024 Oct 22; 98(10):e0101624.